Paravertebral Block for Improvement of Quality of Recovery Following Cardiac Surgery

NCT ID: NCT06008821

Last Updated: 2024-01-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 224 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-13
• Study Completion Date: 2025-11-30

Brief Summary

This study aims to evaluate the efficacy of bilateral, paravertebral blockade (intervention) against sham blocks (control) placed prior to sternotomy in improving quality of recovery following cardiac surgery.

Primary outcome: The hypothesis is that bilateral single-shot PVB at the thoracic spinal segmental levels T3/4, compared with sham blocks, improve the Quality of Recovery-15 (QoR-15) score at 24 hours following cardiac surgery by a minimally clinically important difference of 8.0 or greater.

Secondary outcomes: The hypothesis is that the intervention will reduce pain scores, opioid requirements, and related side effects; improve respiratory mechanics; and facilitate a better first night's rest/sleep in the first 24-48 hours compared to sham blocks.

Detailed Description

This will be a triple-blinded, individually-randomized, single-centered, placebo-controlled trial in which patients will be randomly allocated to two study groups in a 1:1 ratio.

Randomization: The investigators will randomize patients in blocks of 4 or 6. The randomization sequence will be generated online using Sealed Envelope (sealedenvelope.com) . Allocation to treatment versus control will be placed in sealed envelopes. The envelopes will be sequentially numbered, signed and opaque, with the randomization group insert wrapped in foil, and further blocked by carbon paper. On the day of surgery, the regional anesthesiologist be provided the envelope by the research assistant. They will to open it in private, and then destroy its contents immediately upon reading the allocation card.

This study observes blinding of the patients, anesthesiologists, surgeons, nurses, outcome collectors, and data analysts. Only the regional anesthesiologist performing the intervention will be unblinded. To preserve blinding for everyone else, only the regional anesthesiologist and anesthesia assistant will be present in the room at the time of block. Windows on the operating room doors will be covered and a sign mounted to limit entry unless there is an emergency.

Eligible patients will be identified in the Pre-assessment Clinic (PAC) or the inpatient ward. Potentially eligible participants will be screened for significant cognitive impairment, and those scoring 1-2 on the Mini-Cog will be excluded. Enrolled patients will complete a baseline QoR-15 survey. Patients will then be provided a study information package which they can then review on their own time. On the day of surgery, the unblinded regional anesthesiologist will receive information on patient allocation from sealedenvelopes.com and perform the study procedure in the operating room with arterial line monitoring prior to induction of anesthesia. anesthesiologist.

Patients will remain intubated following surgery and be transferred to the CSICU where they are usually extubated within 4-6 hours. Following extubation, patients will receive pain management using hydromorphone IV until transfer to the ward or for the first 24 hours (whichever comes first). For the remainder of the study, the patient will be prescribed a standard postoperative pain control regimen and management will be at the discretion of attending CSICU intensivist, cardiac surgeon or nurse practitioner without influence from this study.

All patients will be followed from the time of randomization thereafter until the common study end date (to be determined, approximately 2 years after the first patient randomized). Primary analysis will be intent to treat.

Statistical Analysis

Sample size: A sample size of n = 112 per group, or total of N=224 patients will be required to reject a null hypothesis that there is no difference in QoR-15 at 24 hours (Student's t test), at a 2-sided alpha of 0.05, and a power of 80% (UBC Sample Size Calculator). This is based off a Minimally Clinically Important Difference of 8.0 in a mixed population of surgical patients reported by Myles et al. At St. Paul's Hospital, the investigators conducted a preliminary prospective study assessing QoR-15 scores in 70 patients approximately 24 hours following cardiac surgery found a lower mean (SD) QoR-15 score of 83.47 +/- 19.86 (unpublished data) than what has been published in the original validation study of QoR-15. The investigators used the QoR-15 scores at 24 hours and a MCID of 8 to calculate a sample size of n=97 per arm. The sample size will be increased by 15% to account for a dropout rate of 5% and delirium rate of 10% observed at St Paul's Hospital, to arrive at a sample size of n=112 per group, or total of N=224 for the entire study.

Primary analysis: intention-to-treat comparison on QoR-15 score at 24 hours (PVB vs sham block) using Student's t test or Mann-Whitney U test). There will be a secondary efficacy analysis done for per protocol population, which would exclude major protocol deviations. In addition, the investigators will conduct a multiple linear regression analysis between the primary outcome of QoR-15 score at 24 hours and treatment group adjusted for baseline QoR-15 score and baseline characteristics (age, sex, history of chronic pain prior to surgery, history depression requiring medication, history of anxiety requiring medication, history of poorly-controlled post-surgical pain, surgical risk stratification (Euroscore II). The primary analyses will be conducted at a two-sided significance level of 0.05

Secondary Analysis: Continuous variables including cumulative opioid consumption, simplified PONVIS score, VISmax score, duration of mechanical ventilation and length of stay will be compared using Student's t test or Mann-Whitney U test, or repeated measures ANOVA with Bonferoni correction when applicable. Dichotomous variables such as atrial fibrillation, pulmonary complications, delirium, and adverse events will be compared using Chi-Squared test or Fisher's Exact Test, or repeated measures ANOVA with Bonferroni correction when applicable. Area under the pain intensity curve (AUE) derived from NRS-11 pain scores obtained from the 4th to 48th hour, and QoR-15 scores at baseline, 24 hours, 48 hours and 12 weeks will be analyzed using a mixed models for repeated measures (MMRM), with baseline values, study group, study visit, and the interaction between study visit and study group as covariates. The analysis of secondary outcomes will be conducted at a two-sided significance level of 0.05.

Handling of Missing data: There will be a proportion of patients who will have missing outcomes due to complications such as delirium/confusion, delayed extubation, postoperative bleeding, and hemodynamic instability. It is anticipated that the loss to follow-up to be <15% which is considered in the sample size calculation. All efforts will be made to collect complete data for all patients in this study. Patients will be followed till the study end and will complete all required data collection. In general, missing values observed in the study will be treated as 'missing'. No attempt will be made to impute missing values and only observed values will be used for analysis.

Subgroup and Sensitivity Analysis: The investigators plan to conduct 3 subgroup analyses based on sex, age, and patients with moderate to severe asthma or COPD. Sensitivity analysis will be conducted comparing intent to treat versus per protocol analysis.

Conditions

Post-operative Pain; Post-cardiac Surgery; Cardiac Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Intervention Group

Bilateral, single level, paravertebral blockade with 0.25% ropivicaine

Group Type: EXPERIMENTAL

Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine

Intervention Type: PROCEDURE

60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)

Control Group

Bilateral, single level, subcutaneous sham block with normal saline

Group Type: SHAM_COMPARATOR

Bilateral sham block with normal saline

Intervention Type: PROCEDURE

10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)

Interventions

Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine

60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)

Intervention Type: PROCEDURE

Bilateral sham block with normal saline

10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• All adult (19 years or older)
• English-speaking patients
• Scheduled for elective cardiac surgery with full median sternotomy.

Exclusion Criteria

• Patient refusal, inability to provide consent
• Mini-Cog© Score of 1-2
• emergent surgery
• infection at the site of injection
• empyema
• neoplastic mass in the paravertebral space
• known preoperative coagulopathy
• platelet count < 50 x 109, INR or aPTT exceeding the upper range of normal in the absence of anticoagulant use, patients receiving anticoagulation medications or non-ASA anti-platelet medications that have not been stopped for the appropriate duration in accordance with American Society of Regional Anesthesia and Pain Medicine guidelines (20)
• severe kyphoscoliosis or deformed spines or previous thoracic surgery
• allergy to study medications
• preoperative liver failure (as defined by Child-Pugh B or C)
• chronic pain or opioid use history, alcohol or drug use disorders, major psychiatric or neurodevelopmental disorders
• Moderate to severe pain at baseline.
• preoperative renal failure (as defined by eGFR < 30 mL/min/1.73 m2)
• extremes of weight (BMI > 40 kg/m2, and weight < 50 kg)
• Patients anticipated to require prolonged post-operative ventilation > 24 hours after surgery

• High risk by Euroscore II >=8%) (21-23)
• 3 or more major procedures
• Procedures requiring deep hypothermic circulatory arrest (DHCA)

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Providence Health & Services

OTHER

Sponsor Role: collaborator

Canadian Anesthesiologists' Society

OTHER

Sponsor Role: collaborator

University of British Columbia

OTHER

Sponsor Role: lead

Responsible Party

Terri Sun

Clinical Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Terri Sun, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Locations

St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Terri Sun, M.D.

Role: CONTACT

terri.sun@gmail.com

604-779-7817

Facility Contacts

Terri Sun, M.D.

Role: primary

terri.sun@gmail.com

604-779-7817

Other Identifiers

H23-00055

Identifier Type: -

Identifier Source: org_study_id